The price and value of therapeutic synergy in liver cancer.

Competing Interests: DJP reports grants from GlaxoSmithKline, Bristol Myers Squibb, and Merck Sharp & Dohme for supporting academic trials in oncology; personal payment from Wiley for an Editor in Chief role unrelated to the topic of this Comment; consulting fees from Mina Therapeutics, EISAI, H3B, AstraZeneca, DaVolterra, Avamune, Bristol Myers Squibb, and Roche for supporting research in oncology unrelated to the topic of this Comment; speaker's fees from Roche, Bristol Myers Squibb, EISAI, and Ewopharma unrelated to the topic of this Comment; travel support from Merck Sharp & Dohme and Bayer; and participation on advisory boards for Astra Zeneca, EISAI, and H3B unrelated to the topic of this Comment. CC reports consulting fees from Eisai, Ipsen, and Merck Sharp & Dohme for supporting research in liver cancer unrelated to the topic of this Comment. All the other authors declare no competing interests.